At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 129 enrolled
Drug / intervention
Nivolumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Single-arm Phase II Safety Study of Nivolumab in Participants With Advanced or Metastatic Non-small Cell Lung Cancer Who Have Progressed During or After Receiving at Least One Prior Systemic Regimen (CheckMate 907: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 907)
In Brief
A Phase 2 clinical trial evaluating Nivolumab for Non-Small Cell Lung Cancer. Completed, enrolled 129 participants across 17 sites in 5 countries.
Detailed Summary
A study to evaluate the safety of Nivolumab in participants with advanced or metastatic non-small cell lung cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesCanada, Japan, Romania, South Africa, United States
CollaboratorsOno Pharmaceutical Co., Ltd.
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 2017
Enrollment StartJun 2017
Primary CompletionFeb 2021
Study CompletionMar 2022
TodayJul 2026
First PostedMar 27, 2017
Enrollment StartJun 2, 2017
Primary CompletionFeb 16, 2021
Study CompletionMar 14, 2022
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 9.3 years ago
Interventions
Nivolumabbiological
Specified Dose on Specified Days